97 related articles for article (PubMed ID: 19235015)
1. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma.
Damgaard T; Knudsen LM; Dahl IM; Gimsing P; Lodahl M; Rasmussen T
Leuk Lymphoma; 2009 Feb; 50(2):236-46. PubMed ID: 19235015
[TBL] [Abstract][Full Text] [Related]
2. Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma.
Pozdnyakova O; Morgan EA; Li B; Shahsafaei A; Dorfman DM
Leuk Lymphoma; 2012 Oct; 53(10):1905-10. PubMed ID: 22423624
[TBL] [Abstract][Full Text] [Related]
3. CD56 expression in human myeloma cells derived from the neurogenic gene expression: possible role of the SRY-HMG box gene, SOX4.
Iqbal MS; Otsuyama K; Shamsasenjan K; Asaoku H; Kawano MM
Int J Hematol; 2010 Mar; 91(2):267-75. PubMed ID: 20049565
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression of the neural cell adhesion molecule (N-CAM) in a panel of multiple myeloma cell lines.
De Greef C; Van Riet I; Bakkus MH; Van Camp B
Leukemia; 1998 Jan; 12(1):86-93. PubMed ID: 9436925
[TBL] [Abstract][Full Text] [Related]
6. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome.
Koumpis E; Tassi I; Malea T; Papathanasiou K; Papakonstantinou I; Serpanou A; Tsolas E; Kapsali E; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
Pathol Res Pract; 2021 Sep; 225():153567. PubMed ID: 34352440
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.
Ioannou MG; Stathakis E; Lazaris AC; Papathomas T; Tsiambas E; Koukoulis GK
Pathol Oncol Res; 2009 Mar; 15(1):25-9. PubMed ID: 18553158
[TBL] [Abstract][Full Text] [Related]
8. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.
Sheth N; Yeung J; Chang H
Leuk Res; 2009 Oct; 33(10):1357-60. PubMed ID: 19201468
[TBL] [Abstract][Full Text] [Related]
9. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
10. NCAM(CD56) and RUNX1(AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia.
Gattenlöhner S; Waller C; Ertl G; Bültmann BD; Müller-Hermelink HK; Marx A
Am J Pathol; 2003 Sep; 163(3):1081-90. PubMed ID: 12937148
[TBL] [Abstract][Full Text] [Related]
11. Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56- and CD56+ multiple myeloma cells.
Sahara N; Takeshita A; Ono T; Sugimoto Y; Kobayashi M; Shigeno K; Nakamura S; Shinjo K; Naito K; Shibata K; Otsuki T; Hayashi H; Ohnishi K
Exp Hematol; 2006 Jun; 34(6):736-44. PubMed ID: 16728278
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.
Kraj M; Sokołowska U; Kopeć-Szlezak J; Pogłód R; Kruk B; Woźniak J; Szpila T
Leuk Lymphoma; 2008 Feb; 49(2):298-305. PubMed ID: 18231917
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
Okura M; Ida N; Yamauchi T
Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
[TBL] [Abstract][Full Text] [Related]
15. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.
Quintanilla-Martinez L; Kremer M; Specht K; Calzada-Wack J; Nathrath M; Schaich R; Höfler H; Fend F
Am J Pathol; 2003 May; 162(5):1449-61. PubMed ID: 12707028
[TBL] [Abstract][Full Text] [Related]
16. Massive central nervous system infiltration by CD56-positive plasma cells in multiple myeloma.
Lopes AC; Xavier FD; de Souza Barroso R; Gomes HR; Sales MM
Cytopathology; 2017 Apr; 28(2):172-174. PubMed ID: 27489145
[No Abstract] [Full Text] [Related]
17. Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities.
Salama ME; Du S; Efimova O; Heikal NM; Wendlandt E; Toydemir RM; South S; Perkins SL; Hussong JW; Zhan F
Leuk Lymphoma; 2015 Feb; 56(2):426-33. PubMed ID: 24913506
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
[TBL] [Abstract][Full Text] [Related]
19. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
20. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
